Navigation Links
Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone
Date:8/21/2008

PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that its novel small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia. The proteasome is an important cellular structure necessary for the growth and function of cancer cells and inhibition of the proteasome has been shown to promote cell cycle arrest and cancer cell death or apoptosis. Bortezomib, an approved drug for the treatment of multiple myeloma, is based on this mechanism. Telik's proteasome inhibitors are orally active, non-peptide, non-boron based, and thus may lead to a drug candidate that might have advantages over Bortezomib and other proteasome inhibitors.

"The potentially favorable profile of these compounds was achieved through the use of our TRAP(R) computational drug discovery technology," said James Keck, Ph.D., Vice President of Biology at Telik. "We are currently conducting activities necessary to select a potential development candidate."

Preliminary data on Telik's proteasome inhibitor program was presented at the 2008 annual meeting of the American Association for Cancer Research.

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.

This press release contains "forward-looking" statements, including statements regarding the potential qualities and capabilities of drug candidates resulting from the small molecule proteasome inhibitor program described above, including the potential ability of such drug candidates to prevent or stop tumor cell division and starve tumors, and the potential development of any drug candidate to treat cancer. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended June 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SuperGens JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation
2. SuperGens PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
3. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
6. Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
7. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
8. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
9. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
10. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  Levine Cancer Institute ... (CT) unit designed to address lung cancer diagnosis, ... the Carolinas. The mobile lung unit is the ... education and treatment interventions through integrated mobile technology, ... Financial barriers and a lack of public ...
(Date:3/22/2017)... 2017 MarketNewsUpdates.com News Commentary  ... ... CBD oil continues to rise in popularity with consumers, ... are enhancing production through acquiring innovative assets and other ... sector include: Future Farm Technologies Inc (OTC: FFRMF) (CSE: FFT.CN), ...
(Date:3/22/2017)... , March 22, 2017  Varex Imaging Corporation ... entered into a renewed three-year pricing agreement with Toshiba ... supply its computed tomography (CT) tubes for integration into ... This renewed agreement will be effective April 1, 2017. ... this renewed agreement are estimated to be in the ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... The American Society for ... (PA) form for prescribers to improve patients’ access to the revolutionary therapy for ... as part of the article entitled “PCSK9 Inhibitor Access Barriers: Issues and ...
(Date:3/22/2017)... Georgia (PRWEB) , ... March 22, 2017 , ... ... time consuming and frustrating and this tool bypasses that. Healthcare facilities across ... identified an opportunity to offer their clients and hospitals, across the country, an ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... the nation’s leading digital and print media enterprise focused on cancer patients, cancer ... content, has released a special 12-part educational video series, “No Ifs, Ands, or ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... solution provider, today announced that its digital marketing solutions have enabled Children’s Hospital ... investment in 24 months. , Recognizing the value of a digital marketing ...
(Date:3/22/2017)... ... 2017 , ... An intensive search of the medical literature has revealed no ... PhD. He says investigating this possibility, is important because Miami-Dade in 2016 ... infections with HIV. , His findings appear on Analizir.com. . Dr. ...
Breaking Medicine News(10 mins):